Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry

Background and aims - Familial hypercholesterolemia (FH) is amongst the most common genetic disorders encountered in primary care. Yet, only a minority of affected patients is diagnosed and treated. This interim analysis of the CaRe High Registry aims at examining the state of treatment and attainme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schmidt, Nina (VerfasserIn) , Dressel, Alexander (VerfasserIn) , Grammer, Tanja B. (VerfasserIn) , Gouni-Berthold, Ioanna (VerfasserIn) , Julius, Ulrich (VerfasserIn) , Kassner, Ursula (VerfasserIn) , Klose, Gerald (VerfasserIn) , König, Christel (VerfasserIn) , Koenig, Wolfgang (VerfasserIn) , Otte, Britta (VerfasserIn) , Parhofer, Klaus G. (VerfasserIn) , Reinhard, Wibke (VerfasserIn) , Schatz, Ulrike (VerfasserIn) , Schunkert, Heribert (VerfasserIn) , Steinhagen-Thiessen, Elisabeth (VerfasserIn) , Vogt, Anja (VerfasserIn) , Laufs, Ulrich (VerfasserIn) , März, Winfried (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2018
In: Atherosclerosis
Year: 2018, Jahrgang: 277, Pages: 314-322
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2018.08.050
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.atherosclerosis.2018.08.050
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0021915018313613
Volltext
Verfasserangaben:Nina Schmidt, Alexander Dressel, Tanja B. Grammer, Ioanna Gouni-Berthold, Ulrich Julius, Ursula Kassner, Gerald Klose, Christel König, Wolfgang Koenig, Britta Otte, Klaus G. Parhofer, Wibke Reinhard, Ulrike Schatz, Heribert Schunkert, Elisabeth Steinhagen-Thiessen, Anja Vogt, Ulrich Laufs, Winfried März

MARC

LEADER 00000caa a2200000 c 4500
001 1693605287
003 DE-627
005 20230427031645.0
007 cr uuu---uuuuu
008 200331s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.atherosclerosis.2018.08.050  |2 doi 
035 |a (DE-627)1693605287 
035 |a (DE-599)KXP1693605287 
035 |a (OCoLC)1341311586 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schmidt, Nina  |e VerfasserIn  |0 (DE-588)1162307811  |0 (DE-627)1025885155  |0 (DE-576)507332652  |4 aut 
245 1 0 |a Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany  |b The CaReHigh Registry  |c Nina Schmidt, Alexander Dressel, Tanja B. Grammer, Ioanna Gouni-Berthold, Ulrich Julius, Ursula Kassner, Gerald Klose, Christel König, Wolfgang Koenig, Britta Otte, Klaus G. Parhofer, Wibke Reinhard, Ulrike Schatz, Heribert Schunkert, Elisabeth Steinhagen-Thiessen, Anja Vogt, Ulrich Laufs, Winfried März 
264 1 |c 2018 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 31.03.2020 
520 |a Background and aims - Familial hypercholesterolemia (FH) is amongst the most common genetic disorders encountered in primary care. Yet, only a minority of affected patients is diagnosed and treated. This interim analysis of the CaRe High Registry aims at examining the state of treatment and attainment of lipid goals in German FH patients. - Methods - The CaRe High registry includes FH patients from lipid clinics and private practices. Data have been collected using questionnaires filled in by the recruiting physicians and by interviewing the participating patients. - Results - We examined 512FH patients diagnosed according to clinical criteria. Median age at the time of the first FH diagnosis was 39 (25th and 75th percentile: 27-50) years, median treatment naïve LDL cholesterol (LDL-C) was 239.4mg/dl (6.19mmol/l), 25th to 75th percentile 191.8-342.5mg/dl (4.96-8.86mmol/l). 27% of the participants did not receive lipid-lowering drugs. Among the patients treated with lipid-lowering drugs, 19% received a PCSK9 inhibitor (PCSK9i) in combination with a statin, 9% were treated with a PCSK9i alone and 3% were treated with a combination of PCSK9i and a non-statin drug. Patients with pre-existing CVD were more likely to be treated with lipid-lowering drugs and more likely to receive a PCSK9i, but LDL-C targets were only achieved by a minority of patients (<20%). Gap to target LDL-C was lowest and the median achieved LDL-C reduction was 1.4 times higher with PCSK9i treatment than with (oral) lipid-lowering therapy without PCSK9i. - Conclusions - The Care High registry has included patients with the typical clinical features of familial hypercholesterolemia. PCSK9i treatment in addition to standard therapy allows attainment of target values in many patients with initially very high LDL-C. 
650 4 |a CaRe High registry 
650 4 |a Familial hypercholesterolemia 
650 4 |a LDL-C goal attainment 
650 4 |a PCSK9 inhibitor 
700 1 |a Dressel, Alexander  |d 1964-  |e VerfasserIn  |0 (DE-588)140815465  |0 (DE-627)703796755  |0 (DE-576)320908615  |4 aut 
700 1 |a Grammer, Tanja B.  |d 1972-  |e VerfasserIn  |0 (DE-588)1030134952  |0 (DE-627)734830041  |0 (DE-576)377941018  |4 aut 
700 1 |a Gouni-Berthold, Ioanna  |e VerfasserIn  |0 (DE-588)1179821394  |0 (DE-627)1067487573  |0 (DE-576)518349039  |4 aut 
700 1 |a Julius, Ulrich  |d 1944-  |e VerfasserIn  |0 (DE-588)107179776  |0 (DE-627)620221151  |0 (DE-576)17723217X  |4 aut 
700 1 |a Kassner, Ursula  |e VerfasserIn  |0 (DE-588)115380087X  |0 (DE-627)1015315720  |0 (DE-576)500563136  |4 aut 
700 1 |a Klose, Gerald  |e VerfasserIn  |0 (DE-588)1090923112  |0 (DE-627)851726801  |0 (DE-576)461193965  |4 aut 
700 1 |a König, Christel  |e VerfasserIn  |4 aut 
700 1 |a Koenig, Wolfgang  |e VerfasserIn  |4 aut 
700 1 |a Otte, Britta  |e VerfasserIn  |4 aut 
700 1 |a Parhofer, Klaus G.  |e VerfasserIn  |0 (DE-588)129376345  |0 (DE-627)626124638  |0 (DE-576)322783305  |4 aut 
700 1 |a Reinhard, Wibke  |d 1977-  |e VerfasserIn  |0 (DE-588)128627506  |0 (DE-627)376934085  |0 (DE-576)187319286  |4 aut 
700 1 |a Schatz, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Schunkert, Heribert  |d 1959-  |e VerfasserIn  |0 (DE-588)111249732  |0 (DE-627)500675104  |0 (DE-576)289696844  |4 aut 
700 1 |a Steinhagen-Thiessen, Elisabeth  |d 1946-  |e VerfasserIn  |0 (DE-588)109639383  |0 (DE-627)597664501  |0 (DE-576)305642081  |4 aut 
700 1 |a Vogt, Anja  |e VerfasserIn  |4 aut 
700 1 |a Laufs, Ulrich  |d 1969-  |e VerfasserIn  |0 (DE-588)1095500791  |0 (DE-627)856114243  |0 (DE-576)462980804  |4 aut 
700 1 |a März, Winfried  |d 1958-  |e VerfasserIn  |0 (DE-588)1027603599  |0 (DE-627)729463605  |0 (DE-576)373454635  |4 aut 
773 0 8 |i Enthalten in  |t Atherosclerosis  |d Amsterdam [u.a.] : Elsevier Science, 1970  |g 277(2018), Seite 314-322  |h Online-Ressource  |w (DE-627)306654091  |w (DE-600)1499887-7  |w (DE-576)081984545  |x 1879-1484  |7 nnas  |a Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany The CaReHigh Registry 
773 1 8 |g volume:277  |g year:2018  |g pages:314-322  |g extent:9  |a Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany The CaReHigh Registry 
856 4 0 |u https://doi.org/10.1016/j.atherosclerosis.2018.08.050  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0021915018313613  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200331 
993 |a Article 
994 |a 2018 
998 |g 1027603599  |a März, Winfried  |m 1027603599:März, Winfried  |d 60000  |d 65300  |e 60000PM1027603599  |e 65300PM1027603599  |k 0/60000/  |k 1/60000/65300/  |p 18  |y j 
998 |g 1030134952  |a Grammer, Tanja B.  |m 1030134952:Grammer, Tanja B.  |d 60000  |d 65300  |e 60000PG1030134952  |e 65300PG1030134952  |k 0/60000/  |k 1/60000/65300/  |p 1  |x j 
999 |a KXP-PPN1693605287  |e 3616387787 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1693605287","name":{"displayForm":["Nina Schmidt, Alexander Dressel, Tanja B. Grammer, Ioanna Gouni-Berthold, Ulrich Julius, Ursula Kassner, Gerald Klose, Christel König, Wolfgang Koenig, Britta Otte, Klaus G. Parhofer, Wibke Reinhard, Ulrike Schatz, Heribert Schunkert, Elisabeth Steinhagen-Thiessen, Anja Vogt, Ulrich Laufs, Winfried März"]},"note":["Gesehen am 31.03.2020"],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"person":[{"role":"aut","display":"Schmidt, Nina","given":"Nina","family":"Schmidt"},{"family":"Dressel","given":"Alexander","display":"Dressel, Alexander","role":"aut"},{"display":"Grammer, Tanja B.","role":"aut","family":"Grammer","given":"Tanja B."},{"given":"Ioanna","family":"Gouni-Berthold","role":"aut","display":"Gouni-Berthold, Ioanna"},{"role":"aut","display":"Julius, Ulrich","given":"Ulrich","family":"Julius"},{"family":"Kassner","given":"Ursula","display":"Kassner, Ursula","role":"aut"},{"display":"Klose, Gerald","role":"aut","family":"Klose","given":"Gerald"},{"role":"aut","display":"König, Christel","given":"Christel","family":"König"},{"given":"Wolfgang","family":"Koenig","role":"aut","display":"Koenig, Wolfgang"},{"display":"Otte, Britta","role":"aut","family":"Otte","given":"Britta"},{"family":"Parhofer","given":"Klaus G.","display":"Parhofer, Klaus G.","role":"aut"},{"family":"Reinhard","given":"Wibke","display":"Reinhard, Wibke","role":"aut"},{"family":"Schatz","given":"Ulrike","display":"Schatz, Ulrike","role":"aut"},{"display":"Schunkert, Heribert","role":"aut","family":"Schunkert","given":"Heribert"},{"family":"Steinhagen-Thiessen","given":"Elisabeth","display":"Steinhagen-Thiessen, Elisabeth","role":"aut"},{"given":"Anja","family":"Vogt","role":"aut","display":"Vogt, Anja"},{"family":"Laufs","given":"Ulrich","display":"Laufs, Ulrich","role":"aut"},{"given":"Winfried","family":"März","role":"aut","display":"März, Winfried"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1016/j.atherosclerosis.2018.08.050"],"eki":["1693605287"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"part":{"volume":"277","extent":"9","year":"2018","pages":"314-322","text":"277(2018), Seite 314-322"},"pubHistory":["Nachgewiesen 11.1970 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"issn":["1879-1484"],"zdb":["1499887-7"],"eki":["306654091"]},"origin":[{"publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science","dateIssuedDisp":"[1970?]-"}],"recId":"306654091","title":[{"title_sort":"Atherosclerosis","title":"Atherosclerosis"}],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"note":["Gesehen am 14.10.2020"],"disp":"Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany The CaReHigh RegistryAtherosclerosis"}],"title":[{"title_sort":"Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany","title":"Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany","subtitle":"The CaReHigh Registry"}]} 
SRT |a SCHMIDTNINLIPIDMODIF2018